An Open-Label, Expanded Access Program with Nivolumab (ONO-4538) for cancer of unknown primary (CUP) (NivoCUP-2) Biomarker study (WJOG14620MTR)
Latest Information Update: 28 Oct 2021
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Biomarker; Expanded access; Therapeutic Use
- Acronyms NivoCUP-2; WJOG14620MTR
- 25 Oct 2021 Status changed from not yet recruiting to recruiting.
- 20 May 2021 New trial record